Insulin Sensitivity of Suppression of Endogenous Glucose Production Is the Single Most Important Determinant of Glucose Tolerance
- 1Emergency and Cardiovascular Medicine
- 2Endocrinology, and
- 3Anaesthesiology, Karolinska Hospital and Institute, Stockholm, Sweden
Abstract
Hyperglycemia results from an imbalance between endocrine pancreatic function and hepatic and extrahepatic insulin sensitivity. We studied 57 well-matched Swedish men with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), or mild diabetes. Oral glucose tolerance and insulin release were assessed during an oral glucose tolerance test (OGTT). Insulin sensitivity and glucose turnover were determined during a two-step euglycemic insulin clamp (infusion 0.25 and 1.0 mU · kg–1 · min–1). High-performance liquid chromatography–purified [6-3H]glucose was used as a tracer. During low-insulin infusion, the rate of endogenous glucose production (EGP) decreased more in subjects with NGT than in subjects with IGT or diabetes (δ rate of appearance [Ra] 1.25 ± 0.10 vs. 0.75 ± 0.14 vs. 0.58 ± 0.09 mg · kg–1 · min–1, P < 0.001). The corresponding rates of glucose infusion during the high-dose insulin infusion (M values) were 8.3 ± 0.6 vs. 5.4 ± 0.9 vs. 4.7 ± 0.4 mg · kg–1 · min–1 (P < 0.001). A total of 56% of the variation in glucose area under the curve (AUC) during OGTT (glucose AUC) was mainly explained by δ Ra (increase in multiple R2 0.42) but also by δ Rd (rate of disapperance) (increase in multiple R2 0.05), and the early insulin response during OGTT contributed significantly (increase in multiple R2 0.07). When M value was included in the model, reflecting extrahepatic insulin sensitivity, it contributed to 20% of the variation in glucose AUC, and together with the incremental insulin response (increase in multiple R2 0.21), it explained 45% of the variation. In conclusion, insulin sensitivity of suppression of EGP plays the most important role in the determination of blood glucose response during OGTT.
Footnotes
-
Address correspondence and reprint requests to Peter Båvenholm, Department of Emergency and Cardiovascular Medicine, Division of Internal Medicine, Karolinska Hospital, S-171 76 Stockholm, Sweden. E-mail: peter.bavenholm{at}ks.se.
Received for publication 28 August 2000 and accepted in revised form 15 March 2001.
ANOVA, analysis of variance; AUC, area under the curve; EGP, endogenous glucose production; FFA, free fatty acid; HPLC, high-performance liquid chromatography; IGT, impaired glucose tolerance; LBM, lean body mass; MSTI, matched-step tracer infusion; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test; Ra, rate of appearance; Rd, rate of disappearance; RIA, radioimmunoassay.











